DATE E-FILED: February 25, 2011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Henning WALCZAK

Application No. 10/551,004

Filed: April 12, 2007

For: FC FUSION PROTEINS

Art Unit: 1647

Confirmation No.: 1454

Examiner: LOCKARD, Jon McClelland

Atty. Docket: 20479.0004.PCUS00

Information Disclosure Statement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- □ 1. This Information Disclosure Statement is being filed;
 - □ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - □ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - □ c. Before the mailing date of a first Office Action on the merits;
 - □ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was first cited in any communication from a

 foreign patent office in a counterpart foreign application not more
 than three months prior to the filing of this Information Disclosure

 Statement. 37 C.F.R. § 1.97(e)(1), or

- □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
- c. The U.S. Patent and Trademark Office is hereby authorized to charge our Deposit Account No. 08-3038 the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p), referencing docket number 20479.0004.PCUS00.
- □ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - □ b. I hereby state that no item of information in this Information Disclosure

 Statement was cited in a communication from a foreign patent
 office in a counterpart foreign application, and, to my knowledge
 after making reasonable inquiry, no item of information contained
 in this Information Disclosure Statement was known to any
 individual designated in 37 C.F.R. § 1.56(c) more than three
 months prior to the filing of this Information Disclosure Statement.

 37 C.F.R. § 1.97(e)(2).

□ 4.	Relevance of the non-English language document(s) is discussed in the present specification.
□ 5.	The document(s) was/were cited in a corresponding foreign application. An
	English language version of the foreign search report is attached for the
	Examiner's information.
□ 6.	A concise explanation of the relevance of the non-English language document(s)
	appears below:
□ 7.	The Examiner's attention is directed to co-pending U.S. Patent Application No.
	, filed, which is directed to related technical subject
	matter. The identification of this U.S. Patent Application is not to be
	construed as a waiver of secrecy as to that application now or upon
	issuance of the present application as a patent. The Examiner is
	respectfully requested to consider the cited application and the art cited
	therein during examination.
□ 8.	Copies of the documents marked * were cited by or submitted to the Office in
	Application No, filed, which is relied upon
	for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these
	documents are not attached. 37 C.F.R. § 1.98(d).
	It is respectfully requested that the Examiner initial and return a copy of the
enclos	ed PTO-1449, and to indicate in the official file wrapper of this patent application
that the documents have been considered.	
	The U.S. Patent and Trademark Office is hereby authorized to charge any fee
deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing	
docket number 20479.0004.PCUS00.	
	Respectfully submitted,
Date:	February 25, 2011 Viola T. Kung, Ph.D. (Reg. No. 41,131)
HOWREY LLP C/O IP DOCKETING DEPARTMENT 1299 Pennsylvania Avenue, NW, Room B-3 Washington DC 20004-2402 Telephone: 650-798-3570 Fax: 650-798-3600	

DM_US:23618510_1